12.70USD+2.26%Mkt Cap: —P/E: —1d ago
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly inters…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap—
Enterprise Value1.26B $
Revenue (TTM)59.51M $
Gross Profit-222.82M $
Net Income (TTM)-399.98M $
Revenue/Share0.4980 USD
Last Price12.70 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees377
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS45826J1051
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.04
EV/Revenue21.19
P/S—
P/B2.22
EPS (TTM)-5.06
EPS (Forward)—
52W Range
11.5061% of range13.47
52W High13.47 USD
52W Low11.50 USD
Profitability
Gross Margin0.00%
Oper. Margin-1472.26%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.44%
ROA-30.14%
Growth
Revenue Growth-46.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-346.64M $
CapEx (TTM)—
FCF Margin-419.83%
FCF Yield—
Net Debt-364.35M $
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity10.09
Current Ratio6.65
Quick Ratio5.61
Book Value/Sh5.197 USD
Cash/Share3.124 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.43.42M
Float134.42M
Insiders3.86%
Institutions99.88%
Technical
SMA 5027.81 (-54.3%)
SMA 20033.27 (-61.8%)
Beta1.79
S&P 52W Chg20.80%
Avg Vol (30d)23.79K
Avg Vol (10d)2.88K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—